The gene for the most common and severe form of autosomal dominant polycystic kidney disease, PKD1, encodes a 14 kb mRNA that is predicted to result in an integral membrane protein of 4302 amino acids. The major challenge faced by researchers attempting to complete mutation analysis of the PKD1 gene has been the presence of several homologous loci also located on chromosome 16. Because the sequence of PKD1 and its homologs is nearly identical in the 5′ region of the gene, most traditional approaches to mutation analysis cannot distinguish sequence variants occurring uniquely in PKD1. Therefore, only a small number of mutations have been identified to date and these have all been found in the 3′, unique portion of the gene. In order to begin analysis of the duplicated region of PKD1, we have devised a novel strategy that depends on long-range PCR and a single gene-specific primer from the unique region of the gene to amplify a PKD1-specific template that spans exons 23-34. This 10 kb template, amplified from genomic DNA, can be employed for mutation analysis using a wide variety of sequence-based approaches. We have used our long-range PCR strategy to begin screening for sequence variants with heteroduplex analysis, and several affected individuals were discovered to have clusters of base pair substitutions in exons 23 and 25. In two patients, these changes, identified in exon 23, would be predicted to result in multiple amino acid substitutions in a short stretch of the protein. This clustering of base pair substitutions is unusual and suggests that mutation may result from unique structural features of the PKD1 gene.
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited disorders in humans, with an incidence of 1:1000. The disease is characterized by the progressive replacement of renal parenchyma by gradually enlarging cysts. Approximately 50% of affected individuals develop renal failure and these patients comprise ∼4-5% of the dialysis population in the United States. Although most affected individuals come to medical attention because of renal disease, ADPKD is a systemic condition with a number of other associated manifestations, including hepatic cysts, cerebral aneurysms and cardiac valvular abnormalities (1) .
The gene for the most common and severe form of ADPKD, PKD1, extends over ∼50 kb of genomic DNA and contains 46 exons that encode a 14 kb mRNA ( Fig. 1) (2) (3) (4) (5) . Polycystin, the PKD1 gene product, is predicted to be an integral membrane protein of 4302 amino acids that is thought to be involved in cell-cell or cell-matrix interactions. Despite intense screening by many groups, only a small number of mutations have been reported (2, (6) (7) (8) (9) (10) (11) (12) , and little is known concerning how different mutations within the gene might play a role in generating observed differences in clinical profile.
The largest obstacle faced by researchers in completing this genetic analysis for PKD1 has been distinguishing it from a family of homologs that map elsewhere on chromosome 16 (2, 13) . Approximately 70% of this gene, beginning with its 5′ end, is duplicated in at least three other loci located more proximally on chromosome 16 ( Fig. 1) . The sequence identity is >95% in the region of similarity. Consequently, almost all of the reported mutations since the gene's identification in 1994 have been clustered in the single copy region of the gene which is amenable to study (2, (6) (7) (8) (9) (10) (11) (12) . Some authors have estimated that ∼85% of mutations in PKD1 may be point mutations in the 5′ duplicated region of the gene (8) . This area of the gene is predicted to encode the large extracellular amino-terminus which includes two leucine-rich repeats, domains with homology to c-type lectin and LDL-A among others. Each structural unit may *To whom correspondence should be addressed. Tel: +1 410 614 1650; Fax: +1 410 955 0485; Email: ggermino@welchlink.welch.jhu.edu Figure 1 . The genomic structure of the PKD1 gene is depicted, including its 46 exons, unique protein domains and an unusual ∼2.5 kb polypyrimidine tract in intron 21 . Approximately 70% of the gene is duplicated in several copies elsewhere on chromosome 16 (stippled box). The relative position of primers used to amplify PKD1-specific templates (3′LR) is shown, along with the location of other PCR products (EJ2) and probes (pL1-4) used (see text). The black rectangle in intron 21 represents the 2.5 kb polypyrimidine tract.
have a unique role in regulating cell-cell or cell-matrix interactions and, therefore, it is conceivable that mutations in particular domains could result in distinct phenotypes. Any approach that is developed for comprehensive mutation detection in this region of the gene, however, will require locus-specific reagents that will distinguish PKD1 from its homologs.
We have developed a strategy that employs long-range PCR of genomic DNA to study exons that lie in the duplicated region of PKD1. The approach uses one PKD1 gene-specific primer as an anchor, in combination with a primer from the duplicated portion of the gene, to amplify a 10 kb template that includes exons 23-34. We have used a series of control reactions to demonstrate that the template is PKD1-specific and that it can be used to amplify nested, gene-specific fragments for mutation analysis if diluted appropriately. Our method is easy, reproducible and requires only one long-range reaction to analyze all of the exons within the template. Using this strategy, we have begun screening affected individuals and have identified several novel sequence variants in exons 23-25.
RESULTS
The duplicated portion of PKD1 begins with exon 1 and ends in the vicinity of a BamHI restriction site at genomic position 44 621 (accession No. L39891) in intron 34 (Fig. 1, stippled box) (2, 5) . We initially searched for locus-specific sequences that could be used to design primer pairs for each PKD1 exon. This strategy was unsuccessful because we could not find a sufficient number of locus-specific primer pairs (data not shown). As an alternative approach, we reasoned that one could utilize long-range PCR methods to generate locus-specific templates using a single PKD1-specific primer in combination with a suitably designed primer from the duplicated portion of the gene. We tested this strategy using a primer complementary to sequence in the 3′ single copy segment of the gene with primers positioned at various 5′ locations. Attempts to amplify fragments >10 kb were unsuccessful due to the very long polypyrimidine tracts located in introns 21 and 22. However, robust amplification could be achieved using a primer positioned in intron 22 (TWF1) in combination with either KG8R25 or KG8R5 (Fig. 1) . KG8R25 is positioned ∼2700 bp 3′ of the BamHI restriction site while KG8R5 is located in exon 38. Products of ∼10 kb spanning exons 23-34 or 23-38 (3′LR) were generated using genomic DNA as template. Genomic DNA prepared using phenol-chloroform extraction did not yield a PCR product as reliably as did DNA prepared using other protocols.
Two cell lines were used to demonstrate the specificity of the long-range PCR reaction (Fig. 2) . The radiation hybrid, 145.19, contains a small (∼3 Mb) segment of chromosome 16p13.3 which includes PKD1 but lacks the homologs (2, 14) . The rodent-human somatic cell hybrid, N23HA, contains most of chromosome 16 including the homologs, but lacks 16p13.3 (2, 15) . 3′LR (TWF1-KG8R25) can be amplified from genomic DNA of 145.19 and from total human genomic DNA but not from N23HA. Several control reactions were performed to confirm that the selective amplification of 3′LR was not due to problems with the N23HA template. The addition of an equal quantity of N23HA to genomic DNA did not inhibit amplification of 3′LR (data not shown). The same preparation of N23HA, however, could be used successfully as template for other long-range PCR products (>7 kb, data not shown).
The PKD1-specific templates can be used for any genomebased mutation screening strategy. In one application, PKD1-specific templates can be used to screen for small intragenic deletions, insertions or mutations that alter restriction sites or to resolve polymorphisms detected in the duplicated region of PKD1. Figure 3A illustrates one example. It shows a Southern blot of PstI-digested genomic DNA of five affected individuals and one unaffected control sample probed with a radiolabeled cDNA fragment of PKD1 (pL1-4). This fragment spans exons 26-28 and thus is included within 3′LR (Fig. 1) . Differences are evident but it cannot be determined if the PKD1 locus is the source of the observed variability. Figure 3B shows the PstI restriction pattern of 3′LR generated from the same individuals that had variability in Figure 3A . Using this method, no differences are detected. A Southern blot of this digest, probed with pL1-4, also failed to detect the original polymorphic bands (data not shown). Clearly the differences detected by pL1-4 in the original genomic Southern are due to sequence variation involving the homologous loci.
The 3′LR can also be used readily as template in methods that scan for single or oligo base pair changes, such as single strand conformation or heteroduplex analysis. One must take special precautions, however, to avoid co-amplification of fragments from the duplicated loci, since small amounts of total genomic DNA (containing both PKD1 and its homologs) from the original PCR mix contaminate the 3′LR product. The problem of genomic contamination can easily be overcome by diluting the 3′LR products to ≥ 1:10 -4 prior to their use as templates for PCR. This degree of dilution provides an adequate amount of 3′LR template for nested PCR of exons contained within it but no longer contains a sufficient quantity of genomic DNA to support amplification of other fragments. Figure 4 presents illustrative examples. Exons 24 and 25 can be amplified robustly when greatly diluted aliquots of 3′LR are used as template, but not when another, similarly diluted long-range PKD1-specific PCR product that includes exons 2-15 (5′LR) is used (Fig. 4A ). Figure 4B shows that there is insufficient genomic contamination of the 3′LR product at dilutions >1:10 -3 to support detectable amplification of EJ2, a genomic fragment from intron 1 (Fig. 1) . This control has been repeated for at least five different templates (data not shown).
We amplified 3′LR from the genomic DNA of ∼80 affected individuals and 50 normal controls, and have used the samples diluted 1:10 -5 as templates for mutation analysis. Primer pairs were designed flanking each exon except exon 23, whose length necessitated the design of two sets of primer pairs that could be used to amplify overlapping fragments. Table 1 presents the sequences and summarizes the optimal PCR conditions for each primer pair. All 80 samples have been screened for mutations in exons 23-26 using heteroduplex analysis. A subset has also been screened for mutations in exons 27-34.
A number of interesting sequence variants, clustered primarily in exons 23 and 25, have been identified and are summarized in Table 2 . We were unable to obtain enough samples from family members to show co-segregation of all variants. Nonetheless, screening of >100 normal chromosomes failed to detect any of the variants listed in Table 2 , except for one polymorphism in exon 25 (discussed below).
Family material was available for samples JHU273 and XT30. Figure 5 shows the segregation of heteroduplex patterns in exons 23 and 25 in the pedigree of a chromosome 16-linked family, JHU273 (16) . The polymorphism in exon 23 segregates with the disease phenotype (Fig. 5B) while that in exon 25 does not (Fig.   5C ). Sequence analysis revealed that the heteroduplex pattern in exon 23 is due to five isolated base pair changes clustered in a small segment (Fig. 6 ). This unusual pattern was confirmed by sequence analysis of two affected individuals as well as by restriction analysis of DNA samples from all available members of the pedigree (Fig. 7) . The extensive nature of these changes, their segregation with the disease phenotype and their absence in normal individuals strongly suggest that this cluster constitutes the germline PKD1 mutation in this family. It is of note that the affected individual, JHU086, was found to have a similar pattern of clustered base pair substitutions even though the two families are not known to be related ( Table 2 ). The family of JHU086 is of German ethnic origin whereas JHU273 is American and has a mix of ethnic backgrounds. A distant genetic relationship between the two families cannot be excluded, however, since one branch of the JHU273 family originated from Germany in 1803. If the individuals are related, each would have independently acquired another unique base pair change substitution superimposed on the set of four changes common to both. The polymorphism in exon 25 in pedigree JHU273 was discovered to be due to two adjacent base pair substitutions that involve two codons. One of the changes does not alter an amino acid, while the other results in an amino acid substitution of phenylalanine by leucine. Approximately 25% of unrelated, unaffected individuals were also found to have the exon 25 polymorphism. A unique heteroduplex pattern in exon 25 was detected in one affected individual (XT30), however, and this pattern was shared by an affected brother, daughter and niece (data not shown). The sequence variant responsible for the novel pattern was determined to be a single base pair change that results in an amino acid substitution of valine by leucine (Table 2 ). This pattern was also absent in 100 normal chromosomes. Although this change segregates with the disease phenotype and is not seen in normal chromosomes, it is a conservative substitution which may not disrupt the protein structure.
Three other differences also were observed. The mutation in JHU114 results in a non-conservative substitution of arginine for glutamine. This variant was not present in samples from 50 normal controls nor in any of the samples from other affected individuals. JHU187 was discovered to have two unique sequence differences. The first is a silent nucleotide substitution in exon 24 while the second alters a single nucleotide in intron 24 that does not disrupt the consensus donor splice site. It is not possible presently to exclude an effect of this variant on RNA processing. It is important to note that the heteroduplex pattern observed in this individual was not detected in >130 other individuals. All sequence variants have been registered with the International PKD Mutation Registry (http://medoc.gdb.org/pkd/). 
DISCUSSION
Genetic analysis of PKD1 has been hampered by the existence of at least three highly homologous loci on chromosome 16 that are also transcribed. Relatively few mutations have been identified since the gene's discovery, and almost all have been located in the 3′, single copy region of the gene. In this report, we describe a novel strategy for mutation analysis in the duplicated region of PKD1. This method relies on the use of one PKD1-specific primer as an anchor in combination with a primer from the duplicated portion of the gene to amplify an ∼10 kb segment containing exons 23-34. We have used rigorous controls to demonstrate that this template is locus-specific and can be used for nested PCR of smaller fragments after appropriate dilution. These fragments can be analyzed using heteroduplex analysis or any of the other PCR-based methods used for mutation detection.
Other groups of investigators have used the protein truncation test (PTT) (17, 18) to scan for mutations in the duplicated region of PKD1. While the PTT can be used to scan relatively large fragments rapidly for protein-terminating variants, it is incapable of identifying important missense mutations. Another limitation is that its use is restricted to the study of either RNA templates or large exons such as exon 15 in PKD1 (∼3 kb). Our approach has Figure 6 . The heteroduplex pattern in exon 23a of JHU273 is due to five isolated base pair changes (Table 2 ) clustered in a small segment of exon 23. The sequence alignment of a portion of the normal (bottom, blue) and mutant alleles (top, black) is shown. The base pair differences are indicated in red along with the corresponding four amino acid changes. These changes create one restriction site (BstUI, blue arrow) and destroy two (FspI and MslI, green arrow). One change neither created nor destroyed a restriction site. Identical sequence changes were found in amplified products derived from one other affected family member (#2) and confirmed in the remaining affected members of the pedigree by restriction analysis.
several advantages. Amplification with our set of primers (TWF1 and KG8R25) and conditions works reliably when DNA is prepared from blood or tissue using one of many commercially available kits (avoiding the use of phenol-chloroform extraction). Another advantage is that small quantities of source material are sufficient for generating templates. One PCR reaction requires <300 ng of genomic DNA and provides sufficient material for all subsequent studies, since the final reaction is diluted to at least 1:10 -5 prior to use. The method can be amended easily for use in evaluating RNA samples prepared from blood or other tissues and, unlike PTT, should be broadly applicable to other areas of PKD1 since it requires few locus-specific primers. Finally, our approach can also be used to screen for all types of sequence variants.
We have used our long-range genomic PCR strategy successfully to study exons within the duplicated region and have discovered an unusual pattern of mutation in exon 23 of two patients affected with ADPKD. These data are notable in light of our recent discovery that renal cysts in ADPKD are clonal and have acquired mutations of the previously normal allele (16) . Our data suggest that the majority of renal cysts arise as a result of independent mutations, implying a high rate of somatic mutation. The frequency with which 'second hits' occur in PKD1 appears to be greater than that observed in other tumor suppressor genes responsible for renal tumors. These two sets of observations suggest that a new mechanism of mutation may be involved in the pathogenesis of PKD1.
We postulate that unusual features of the PKD1 structure may be responsible for its mutability (3, 16, 19) . PKD1 has three long polypyrimidine tracts within introns 1, 21 and 22, the longest of which is 2.5 kb (intron 21). The tract in intron 21 is the longest polypyrimidine tract sequenced to date, and contains 23 mirror repeats with stem lengths of at least 10 nucleotides (19) . The mirror repeats are likely to form H-DNA structures composed of a triple helix conformation under appropriate conditions. Wang et al. recently have shown that triplex structures can promote localized mutagenesis in cultured cells (20) . The authors discovered that triplex formation mediated through triplex-forming oligonucleotides caused a 10-fold increase in mutation frequency in a cell culture model system. The mutations were observed in a gradient around the site of triple helix formation and included single base pair substitutions, small deletions and multiple simultaneous point mutations. While the majority of variants that we discovered in exons near the polypyrimidine tracts were single base pair changes, two individuals had similar but non-identical sets of clustered base pair changes in exon 23 that result in multiple amino acid substitutions in a short stretch of the protein. The 2 bp normal variant in exon 25 may have arisen via a similar mechanism. This unusual pattern of clustered multiple base pair substitutions is consistent with that associated with triple helix formation and may implicate this novel mechanism of mutation in the molecular pathogenesis of PKD1.
It should be noted that the distance between the largest polypyrimidine tract in intron 21 of PKD1 and the mutations in exon 23 is much larger than in the report of Wang et al. There are several important differences between their study and ours, however, which might explain the discrepancy. First, it is possible that the polypyrimidine tract in intron 22 also forms triplex structures. This could account for the increased mutability of the immediately adjacent exon. Second, the triplex-forming site in the small reporter gene (supFG1) used by Wang et al. is very near its 3′ end while in PKD1 the CT element is centrally located within a 50 kb primary transcript. It is unknown whether this Figure 7 . The JHU273 exon 23 sequence variants segregate with disease in the JHU273 pedigree. Exon 23a was amplified from 3′LR of each family member as described in Materials and Methods and digested with the three restriction enzymes that distinguish the normal and mutant alleles. The lane assignments correspond to those used in Figure 6 . BstUI (top panel) creates two new fragments of 101 and 65 bp in each affected family member (lanes 2 and 6-9). Both FspI and MslI are predicted to cleave the amplified 377 bp fragment of the normal allele once. The mutant allele which lacks the sites is predicted not to cleave with either enzyme. As the lower panels demonstrate, the 377 bp fragment of unaffected family members (lanes 1 and 3-5) is cleaved to completion while the amplified segment of affected individuals is not. A small amount of full-length product is still detectable in the normal samples, even after prolonged incubation with FspI, because of the lower efficiency of FspI. A similar pattern was observed using cloned DNA (data not shown). The shadow band seen in lane 7 of the middle panel is an artifact.
difference would influence the range of sites at risk for mutation via this mechanism. Moreover, the assay used by Wang et al. only detected mutations that resulted in a visible phenotype by altering supFG1 function. The authors note in their discussion that mutations involving sequences outside of the supFG1 gene would have been missed. Finally, one might imagine that a 2.5 kb element that is ∼100 times larger than that used in this artificial system might have a more severe effect because of its tremendous potential for multiple sites of triplex formation. It is impossible to predict a priori how these differences in gene structure would influence outcome.
The remarkable similarity between the mutations discovered in JHU273 and JHU086 is surprising given the relative infrequency of this pattern in the population studied (2/80). While it may be explained by common ancestry, an alternative explanation is that the mutations had arisen independently via the triplex-mediated transcription-coupled repair mechanism described above. Wang et al. found that mutations in their system were not completely random and, in fact, certain patterns recurred multiple times. This might explain why the entire set of mutations seen in JHU273 and JHU086 was not identical. An alternative explanation for these observations could be that the sets of mutations arose by gene conversion events between PKD1 and its homologs. It is possible that the polypyrimidine tracts in introns 21 and 22 (which are present in at least some of the homologous loci, unpublished data) may play a role in promoting this process.
Exons 23 and 25 are predicted to encode portions of polycystin with extensive homology to the receptor for egg jelly (REJ) in the sperm of the sea urchin (21) . This receptor functions during fertilization by binding to glycoproteins in the egg jelly and then inducing the sperm acrosome reaction, an ion channel-regulated event. Analysis of the amino acid sequence of this REJ-like domain in the primitive vertebrate Fugu rubripes shows >75% sequence conservation with human PKD1, suggesting that this region of polycystin may be functionally important (22) . Variants of PKD1 may become pathogenic by disrupting an interaction between polycystin and its ligand.
Finally, our results highlight what we believe will be another important aspect of mutation detection in PKD1. We have detected a number of sequence variants that appear to segregate with the disease phenotype and are not detected in unaffected individuals, yet are predicted to result in conservative amino acid substitutions such as the leucine to valine change in Family 30. Other investigators have reported similar findings (8, 12) . Lacking a functional assay, it is difficult to establish with certainty the pathogenicity of such sequence variants. We predict, given both the size and inherent mutability of the gene, that the affected chromosome in a given family may harbor a number of 'private' variants that are not responsible for the disease phenotype. Investigators seeking to establish genotype-phenotype correlations or perform genetic testing must use the information cautiously until confirmatory functional studies are possible. It will be interesting to determine whether normal variants have any role in modifying disease expression.
MATERIALS AND METHODS

Patient recruitment
Affected individuals were recruited from dialysis centers and nephrology clinics. The diagnosis of ADPKD was established using standard criteria (23, 24) . Family members of probands were recruited to participate after receiving permission from the donors. Blood samples were obtained after receiving informed consent and in accordance with institutional guidelines.
Long-range PCR
DNA was isolated from whole blood using the Puregene kit (Gentra) and the manufacturer's protocol. Genomic DNA (300 ng) was used as template for amplification of an ∼10 kb product (3′LR) using primers TWF1 (5′-CTGCACTGAC-CTCACGCATGT-3′, genomic position 37 678-37 698) and KG8R25 (5′-GTTGCAGCCAAGCCCATGTTA-3′, genomic position 47 320-47 340) or KG8R5 (5′-GCGCTTTGCAGACG-GTAGGCG-3′, genomic position 48 579-48 599). For the cell lines, 145.19 and N23HA, 400 ng of genomic DNA, prepared using the Puregene kit, was used as template. PCR was performed as follows: denaturation at 94_C for 3 min 15 s, 35 cycles of 94_C for 15 s and 68_C for 10 min and a final extension of 72_C for 10 min. The total PCR volume was 50 µl using 4 U of rTth DNA polymerase, XL (Cetus, Perkin Elmer) and a final MgCl 2 concentration of 1.1 mM. A hot start protocol recommended by the manufacturer was also used so that the rTth DNA polymerase, XL was added at 80_C. Products of the long-range PCR reaction were run on a 1% agarose gel to confirm that the reaction was successful prior to proceeding to the next step.
The specificity of 3′LR products was evaluated by testing for the presence of EJ2. This 143 bp fragment is located in intron 1 and is amplified using primers FQF4 (5′-TCGTCATGCG-GAATCCTGACTCTG-3′) and FQR5 (5′-TTCCAAAC-CCCTGCTATGCACATC-3′). PCR was performed using the same conditions as were used for exon 23 (Table 1) .
Heteroduplex analysis
The long-range template 3′LR was diluted serially to 1:10 -5 and used for all subsequent PCR reactions. Two µl of diluted template was used as template for amplification of each exon, using conditions summarized in Table 1 . The total PCR volume was 30 µl using 2 U of Taq DNA polymerase (Boehringer Mannheim), 0.2 µl of dCTP and a final MgCl 2 concentration of 1.5 mM. Fragment exon 23A was digested with XmaI (Boehringer Mannheim) using the manufacturer's recommended conditions prior to heteroduplex analysis, yielding two fragments of 284 and 347 bp.
Heteroduplex analysis was performed using Hydrolink Mutation Detection Enhancement gels (MDE, AT Biochem) following the manufacturer's protocol. Urea was added to the gel to a final concentration of 15% to minimize band broadening. The radiolabeled PCR products were denatured initially by heating at 95_C for 5 min and then allowed to cool to room temperature gradually over 1-2 h before loading. Gels were run at 700 V for 14-16 h, dried and placed on X-Omat XAR film (Kodak) at room temperature and/or on a Phosphoimager cassette (Molecular Dynamics). All novel heteroduplex patterns were confirmed using a second template prepared from the same individual. Exons harboring variants were cloned into pCRII (TA Cloning Kit, Invitrogen) prior to sequencing. In order to distinguish clones containing the normal allele from the novel allele, mixing studies were performed as previously described (16) . At least two independent clones containing the mutant allele were sequenced using an ABI automated sequencer and standard protocols. When possible, sequence differences were confirmed by restriction analysis of nested products derived from two independent 3′LR templates using enzymes whose recognition sites were altered by the changes.
Southern blots
Fifteen µl of 3′LR or 5 µg of genomic DNA were digested in a total volume of 30 µl with 2 U of PstI. The products were run on a 1% agarose gel and transferred using standard techniques to a nylon membrane (Nytran, Schleicher and Schuell). pL1-4 is a cDNA clone whose insert was amplified from first strand cDNA derived from lymphoblast RNA using primers NKG10F4 (5′-CCTCACAGGAGCCGACAG-3′) and NKG9R1 (5′-CGAT-GACGTGCTGCAGGAACC-3′). The insert was labeled with dCTP using Rediprime (Amersham) and hybridized to filters at 65_C. Filters were washed twice with 1× SSC, 1% SDS and twice with 0.1× SSC, 1% SDS at 65_C. Blots were then placed on X-Omat XAR film (Kodak) at -80_C and/or on a Phosphoimager cassette at room temperature (Molecular Dynamics).
